CD19-CAR-γδT
/ Chinese PLA General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 31, 2025
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Initiation date: Feb 2025 ➔ Jul 2025 | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
February 21, 2025
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Chinese PLA General Hospital
New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
February 19, 2025
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CCND1
March 15, 2024
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CCND1
1 to 4
Of
4
Go to page
1